EGFR and prostate adenocarcinoma: In the prostate, higher levels of epithelial EGFR immunoreactivity (EGFR-IR) were seen in prostatic adenocarcinoma than in normal tissue [15], and patients with a tumour tissue pEGFR-IR score in the top 66% bracket showed a poorer disease-specific survival than those cases with a pEGFR-IR score in the bottom 34% [16].